Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228039 | 0.86 | MCHR1 (0.54) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4489001 | 0.83 | MCHR1 (0.63) | MCHR1CHRM1HTR2ACYP2D6LMNA | |
| SCHEMBL5226162 | 0.81 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL6418908 | 0.80 | MCHR1 (0.54) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4485106 | 0.80 | MCHR1 (0.57) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL6370264 | 0.79 | MCHR1 (0.54) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL5230618 | 0.79 | MCHR1 (0.53) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL6366208 | 0.79 | MCHR1 (0.53) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL6366203 | 0.79 | MCHR1 (0.54) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL6366084 | 0.79 | MCHR1 (0.54) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737824-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005103032-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 49/4885HTR2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.